{
    "clinical_study": {
        "@rank": "41849", 
        "arm_group": {
            "arm_group_label": "TAB08", 
            "arm_group_type": "Experimental", 
            "description": "Single TAB08 i.v. infusion"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess safety and tolerability of ascending dosed of TAB08\n      after single i.v. infusion to the adult healthy volunteers. Additionally were assessed\n      infusion speed tolerability, pharmacokinetics and pharmacodynamics of TAB08 after single\n      i.v. infusion and to explore TAB mechanism-of-action biomarkers."
        }, 
        "brief_title": "Open Label Phase 1 Pharmacokinetics and Tolerability Study of Single TAB08 Administration in Healthy Volunteers", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Adult Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult man aged from 18 to 40 years, who agreed to use adequate contraception.\n\n          -  Body mass is at least 60 kg and BMI is within 20-27\n\n          -  Volunteer is in good physical and mental health, as per his medical history and\n             assessment results\n\n          -  Volunteer's laboratory values are normal (or not clinically significant as per\n             Investigator discretion) at screening, including baseline cytokines levels as per\n             RESTORE test results\n\n          -  Volunteer has signed the informed concent.\n\n        Exclusion Criteria:\n\n          -  Any chronic or relapsing illness in the medical history\n\n          -  Any abnormal assessment or laboratory result at screening, which is clinically\n             significant as per Investigator discretion\n\n          -  Active tuberculosis at the time of screening\n\n          -  Any acute illness at the time of study enrollment\n\n          -  Any blood donation within 4 weeks before Study Day 1\n\n          -  Positive result for HBsAG, Hepatitis C, HIV\n\n          -  Continuous use af any medications\n\n          -  Use of any medications within 72 hours before study drug infusion\n\n          -  Use of an investigational treatment within 4 weeks before screening, or within a\n             period of 5 half-lives of the investigational treatment, whichever is longer\n\n          -  High inflammatory cytokines levels as per RESTORE test results after ex vivo PBMC\n             testing"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "31", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01885624", 
            "org_study_id": "TAB08/HS/R1"
        }, 
        "intervention": {
            "arm_group_label": "TAB08", 
            "description": "monoclonal antibody", 
            "intervention_name": "TAB08", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "TAB08", 
            "healthy volunteers"
        ], 
        "lastchanged_date": "September 2, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Yaroslavl", 
                    "country": "Russian Federation", 
                    "zip": "150003"
                }, 
                "name": "Clinical Emergency Hospital of Yaroslavl"
            }
        }, 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_arms": "1", 
        "official_title": "Open Label Phase 1 Pharmacokinetics and Tolerability Study of Single TAB08 Administration in Healthy Volunteers", 
        "overall_official": {
            "affiliation": "Clinical Emergency Hospital of Yaroslavl", 
            "last_name": "Olga B Ershova, Prof.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Russia: Ministry of Health of the Russian Federation", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Incidence of dose-limiting toxicity in every dose cohort", 
            "safety_issue": "Yes", 
            "time_frame": "From study drug infusion (Day 1) untill the end of study (Day 71/141)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01885624"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Theramab LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Theramab LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}